MANGOCEUTICALS, INC. Files 8-K Report

Ticker: MGRX · Form: 8-K · Filed: Oct 3, 2024 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateOct 3, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, financial-reporting

TL;DR

MANGOCEUTICALS, INC. filed an 8-K, likely routine financial updates.

AI Summary

On October 3, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or significant business events were detailed in the provided excerpt.

Why It Matters

This filing indicates MANGOCEUTICALS, INC. is providing updates or submitting required financial documents to the SEC, which is standard corporate disclosure.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative events or financial distress.

Key Players & Entities

FAQ

What specific "Other Events" are being reported by MANGOCEUTICALS, INC. in this 8-K filing?

The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported, only that this item is included.

What "Financial Statements and Exhibits" are being filed by MANGOCEUTICALS, INC.?

The excerpt indicates that "Financial Statements and Exhibits" are part of the filing, but does not specify which ones.

When was the earliest event reported in this 8-K filing for MANGOCEUTICALS, INC.?

The earliest event reported in this 8-K filing for MANGOCEUTICALS, INC. was on October 3, 2024.

What is the principal executive office address for MANGOCEUTICALS, INC.?

The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

What is the SEC file number for MANGOCEUTICALS, INC.?

The SEC file number for MANGOCEUTICALS, INC. is 001-41615.

Filing Stats: 849 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-10-03 08:30:33

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 3, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing